You are here
Incysus Announces Appointment of Joy Bessenger as Senior Vice President, Finance and Strategy
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that Joy E. Bessenger has been appointed Senior Vice President, Finance and Strategy.
Ms. Bessenger has more than 25 years of experience in finance and biotechnology. She most recently served as Chief Financial Officer at 3D Forensic, a San Francisco-based technology company from 2012 until earlier this year. Prior to 3D Forensic, she was the Vice President of Strategy and Development at deCODE Genetics, a global leader in analyzing and understanding the human genome. In that role, Ms. Bessenger led and coordinated strategic financial planning and capital formation, raising over $270 million through multiple transactions. Earlier in her career, Ms. Bessenger held several senior positions in investor relations and investment banking at institutions including Noonan/Russo Communications, Volpe Brown Whelan & Company, Genesis Merchant Group, and Robertson Stephens & Company. Ms. Bessenger received her B.A. from the University of South Florida.
“I am excited to join Incysus at such a pivotal time for the company,” said Ms. Bessenger. “Incysus has already created significant value by understanding the science of genetically modified γδ T cells and; 2018 is expected to be a transformative year as the Company seeks to initiate its clinical programs in leukemia and lymphoma patients undergoing haploidentical stem cell transplantation, and for the treatment of glioblastoma.”
William Ho, Chief Executive Officer of Incysus said, “Ms. Bessenger’s strong background in both biotechnology and finance, as well as her numerous relationships within the investment community make her an excellent choice to help us advance through our next stage of growth. In addition to her financial background, Joy brings significant management experience that will be invaluable as we continue to build Incysus.”
About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. For more information, visit www.incysus.com.
Incysus Therapeutics, Inc.